Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AstraZeneca Submits New Drug Applications For ZACTIMA(TM) In Second-Line Advanced Non-Small Cell Lung Cancer
AstraZeneca (NYSE: AZN) announced the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy. The U.S. and European submissions are supported by data from Phase III clinical studies evaluating the safety and efficacy of vandetanib 100 mg in combination with chemotherapy. Pending approval, the treatment will be marketed as ZACTIMA(TM).

Laugh A Little To Help Protect Heart, Lower Blood Pressure
Laughter is not only an effective stress-reliever, but can be heart-healthy, according to research presented at the American College of Sports Medicine"s 56th Annual Meeting in Seattle. Two separate studies examined the role of a good laugh as it relates to health.
News of the day
Primary Health Care Reforms Will Improve Access, But Opportunities For Aged Care Missed Again, Australia
In response to the release of recommendations from the National Health and Hospital Reform Commission the Australian Nursing Federation welcomed the focus on primary health care and the development of Comprehensive Primary Health Care Centers.
Medical Devices

Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target. The low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system. "We are delighted to strengthen our product portfolio by advancing another novel Nanobody®, discovered using our proprietary Nanobody® platform, into preclinical development. It is well positioned to translate into a superior treatment for rheumatoid arthritis and other autoimmune diseases. There are already three Nanobodies® in clinical development, with our lead programme, ALX-0081, a novel anti-thrombotic, on track to start Phase II in the next few months", commented Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx. About ALX-0061 (IL6R) ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R). It has the potential to differentiate through its high potency, high stability and low molecule weight of only 26kD which should translate into superior tissue penetration, attractive PK/PD and superior safety and efficacy profile compared with a benchmark monoclonal antibody. The involvement of the IL6 pathway in a variety of diseases indicates that multiple indications can be pursued with large market potential including rheumatoid arthritis (RA), Crohn"s disease, Castleman"s disease, multiple myeloma and systemic lupus erythematosus (SLE). College Hill Life Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009